A Proof of Concept Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on Olaparib in Ovarian Cancer

Trial Profile

A Proof of Concept Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on Olaparib in Ovarian Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Cediranib (Primary) ; Olaparib (Primary)
  • Indications Ovarian cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms e-Volve
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jun 2015 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 16 Jun 2015 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top